Publication

Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial

Klazen, C. A. H., Lohle, P. N. M., de Vries, J., Jansen, F. H., Tielbeek, A. V., Blonk, M. C., Venmans, A., van Rooij, W. J. J., Schoemaker, M. C., Juttmann, J. R., Lo, T. H., Verhaar, H. J. J., van der Graaf, Y., van Everdingen, K. J., Muller, A. F., Elgersma, O. E. H., Halkema, D. R., Fransen, H., Janssens, X., Buskens, E. & Mali, W. P. T. M., 2010, In : LANCET. 376, 9746, p. 1085-1092 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Klazen, C. A. H., Lohle, P. N. M., de Vries, J., Jansen, F. H., Tielbeek, A. V., Blonk, M. C., ... Mali, W. P. T. M. (2010). Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. LANCET, 376(9746), 1085-1092. https://doi.org/10.1016/S0140-6736(10)60954-3

Author

Klazen, Caroline A. H. ; Lohle, Paul N. M. ; de Vries, Jolanda ; Jansen, Frits H. ; Tielbeek, Alexander V. ; Blonk, Marion C. ; Venmans, Alexander ; van Rooij, Willem Jan J. ; Schoemaker, Marinus C. ; Juttmann, Job R. ; Lo, Tjoen H. ; Verhaar, Harald J. J. ; van der Graaf, Yolanda ; van Everdingen, Kaspar J. ; Muller, Alex F. ; Elgersma, Otto E. H. ; Halkema, Dirk R. ; Fransen, Hendrik ; Janssens, Xavier ; Buskens, Erik ; Mali, Willem P. Th M. / Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II) : an open-label randomised trial. In: LANCET. 2010 ; Vol. 376, No. 9746. pp. 1085-1092.

Harvard

Klazen, CAH, Lohle, PNM, de Vries, J, Jansen, FH, Tielbeek, AV, Blonk, MC, Venmans, A, van Rooij, WJJ, Schoemaker, MC, Juttmann, JR, Lo, TH, Verhaar, HJJ, van der Graaf, Y, van Everdingen, KJ, Muller, AF, Elgersma, OEH, Halkema, DR, Fransen, H, Janssens, X, Buskens, E & Mali, WPTM 2010, 'Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial', LANCET, vol. 376, no. 9746, pp. 1085-1092. https://doi.org/10.1016/S0140-6736(10)60954-3

Standard

Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II) : an open-label randomised trial. / Klazen, Caroline A. H.; Lohle, Paul N. M.; de Vries, Jolanda; Jansen, Frits H.; Tielbeek, Alexander V.; Blonk, Marion C.; Venmans, Alexander; van Rooij, Willem Jan J.; Schoemaker, Marinus C.; Juttmann, Job R.; Lo, Tjoen H.; Verhaar, Harald J. J.; van der Graaf, Yolanda; van Everdingen, Kaspar J.; Muller, Alex F.; Elgersma, Otto E. H.; Halkema, Dirk R.; Fransen, Hendrik; Janssens, Xavier; Buskens, Erik; Mali, Willem P. Th M.

In: LANCET, Vol. 376, No. 9746, 2010, p. 1085-1092.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Klazen CAH, Lohle PNM, de Vries J, Jansen FH, Tielbeek AV, Blonk MC et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. LANCET. 2010;376(9746):1085-1092. https://doi.org/10.1016/S0140-6736(10)60954-3


BibTeX

@article{d48b530c6de64ff68d16a7d47d80db66,
title = "Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial",
abstract = "Background Percutaneous vertebroplasty is increasingly used for treatment of pain in patients with osteoporotic vertebral compression fractures, but the efficacy, cost-effectiveness, and safety of the procedure remain uncertain. We aimed to clarify whether vertebroplasty has additional value compared with optimum pain treatment in patients with acute vertebral fractures.Methods Patients were recruited to this open-label prospective randomised trial from the radiology departments of six hospitals in the Netherlands and Belgium. Patients were aged 50 years or older, had vertebral compression fractures on spine radiograph (minimum 15{\%} height loss; level of fracture at Th5 or lower; bone oedema on MRI), with back pain for 6 weeks or less, and a visual analogue scale (VAS) score of 5 or more. Patients were randomly allocated to percutaneous vertebroplasty or conservative treatment by computer-generated randomisation codes with a block size of six. Masking was not possible for participants, physicians, and outcome assessors. The primary outcome was pain relief at 1 month and 1 year as measured by VAS score. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT00232466.Findings Between Oct 1,2005, and June 30,2008, we identified 431 patients who were eligible for randomisation. 229 (53{\%}) patients had spontaneous pain relief during assessment, and 202 patients with persistent pain were randomly allocated to treatment (101 vertebroplasty, 101 conservative treatment). Vertebroplasty resulted in greater pain relief than did conservative treatment; difference in mean VAS score between baseline and 1 month was -5.2 (95{\%} CI -5.88 to -4.72) after vertebroplasty and -2.7 (-3.22 to -1.98) after conservative treatment, and between baseline and 1 year was -5.7 (-6.22 to -4.98) after vertebroplasty and -3-7 (-4.35 to -3.05) after conservative treatment. The difference between groups in reduction of mean VAS score from baseline was 2.6 (95{\%} CI 1.74-3.37, pInterpretation In a subgroup of patients with acute osteoporotic vertebral compression fractures and persistent pain, percutaneous vertebroplasty is effective and safe. Pain relief after vertebroplasty is immediate, is sustained for at least a year, and is significantly greater than that achieved with conservative treatment, at an acceptable cost.",
keywords = "QUALITY-OF-LIFE, PERCUTANEOUS VERTEBROPLASTY, FOLLOW-UP, PAIN RELIEF, KYPHOPLASTY, IMPROVEMENT",
author = "Klazen, {Caroline A. H.} and Lohle, {Paul N. M.} and {de Vries}, Jolanda and Jansen, {Frits H.} and Tielbeek, {Alexander V.} and Blonk, {Marion C.} and Alexander Venmans and {van Rooij}, {Willem Jan J.} and Schoemaker, {Marinus C.} and Juttmann, {Job R.} and Lo, {Tjoen H.} and Verhaar, {Harald J. J.} and {van der Graaf}, Yolanda and {van Everdingen}, {Kaspar J.} and Muller, {Alex F.} and Elgersma, {Otto E. H.} and Halkema, {Dirk R.} and Hendrik Fransen and Xavier Janssens and Erik Buskens and Mali, {Willem P. Th M.}",
year = "2010",
doi = "10.1016/S0140-6736(10)60954-3",
language = "English",
volume = "376",
pages = "1085--1092",
journal = "The Lancet",
issn = "0140-6736",
publisher = "ELSEVIER SCIENCE INC",
number = "9746",

}

RIS

TY - JOUR

T1 - Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II)

T2 - an open-label randomised trial

AU - Klazen, Caroline A. H.

AU - Lohle, Paul N. M.

AU - de Vries, Jolanda

AU - Jansen, Frits H.

AU - Tielbeek, Alexander V.

AU - Blonk, Marion C.

AU - Venmans, Alexander

AU - van Rooij, Willem Jan J.

AU - Schoemaker, Marinus C.

AU - Juttmann, Job R.

AU - Lo, Tjoen H.

AU - Verhaar, Harald J. J.

AU - van der Graaf, Yolanda

AU - van Everdingen, Kaspar J.

AU - Muller, Alex F.

AU - Elgersma, Otto E. H.

AU - Halkema, Dirk R.

AU - Fransen, Hendrik

AU - Janssens, Xavier

AU - Buskens, Erik

AU - Mali, Willem P. Th M.

PY - 2010

Y1 - 2010

N2 - Background Percutaneous vertebroplasty is increasingly used for treatment of pain in patients with osteoporotic vertebral compression fractures, but the efficacy, cost-effectiveness, and safety of the procedure remain uncertain. We aimed to clarify whether vertebroplasty has additional value compared with optimum pain treatment in patients with acute vertebral fractures.Methods Patients were recruited to this open-label prospective randomised trial from the radiology departments of six hospitals in the Netherlands and Belgium. Patients were aged 50 years or older, had vertebral compression fractures on spine radiograph (minimum 15% height loss; level of fracture at Th5 or lower; bone oedema on MRI), with back pain for 6 weeks or less, and a visual analogue scale (VAS) score of 5 or more. Patients were randomly allocated to percutaneous vertebroplasty or conservative treatment by computer-generated randomisation codes with a block size of six. Masking was not possible for participants, physicians, and outcome assessors. The primary outcome was pain relief at 1 month and 1 year as measured by VAS score. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT00232466.Findings Between Oct 1,2005, and June 30,2008, we identified 431 patients who were eligible for randomisation. 229 (53%) patients had spontaneous pain relief during assessment, and 202 patients with persistent pain were randomly allocated to treatment (101 vertebroplasty, 101 conservative treatment). Vertebroplasty resulted in greater pain relief than did conservative treatment; difference in mean VAS score between baseline and 1 month was -5.2 (95% CI -5.88 to -4.72) after vertebroplasty and -2.7 (-3.22 to -1.98) after conservative treatment, and between baseline and 1 year was -5.7 (-6.22 to -4.98) after vertebroplasty and -3-7 (-4.35 to -3.05) after conservative treatment. The difference between groups in reduction of mean VAS score from baseline was 2.6 (95% CI 1.74-3.37, pInterpretation In a subgroup of patients with acute osteoporotic vertebral compression fractures and persistent pain, percutaneous vertebroplasty is effective and safe. Pain relief after vertebroplasty is immediate, is sustained for at least a year, and is significantly greater than that achieved with conservative treatment, at an acceptable cost.

AB - Background Percutaneous vertebroplasty is increasingly used for treatment of pain in patients with osteoporotic vertebral compression fractures, but the efficacy, cost-effectiveness, and safety of the procedure remain uncertain. We aimed to clarify whether vertebroplasty has additional value compared with optimum pain treatment in patients with acute vertebral fractures.Methods Patients were recruited to this open-label prospective randomised trial from the radiology departments of six hospitals in the Netherlands and Belgium. Patients were aged 50 years or older, had vertebral compression fractures on spine radiograph (minimum 15% height loss; level of fracture at Th5 or lower; bone oedema on MRI), with back pain for 6 weeks or less, and a visual analogue scale (VAS) score of 5 or more. Patients were randomly allocated to percutaneous vertebroplasty or conservative treatment by computer-generated randomisation codes with a block size of six. Masking was not possible for participants, physicians, and outcome assessors. The primary outcome was pain relief at 1 month and 1 year as measured by VAS score. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT00232466.Findings Between Oct 1,2005, and June 30,2008, we identified 431 patients who were eligible for randomisation. 229 (53%) patients had spontaneous pain relief during assessment, and 202 patients with persistent pain were randomly allocated to treatment (101 vertebroplasty, 101 conservative treatment). Vertebroplasty resulted in greater pain relief than did conservative treatment; difference in mean VAS score between baseline and 1 month was -5.2 (95% CI -5.88 to -4.72) after vertebroplasty and -2.7 (-3.22 to -1.98) after conservative treatment, and between baseline and 1 year was -5.7 (-6.22 to -4.98) after vertebroplasty and -3-7 (-4.35 to -3.05) after conservative treatment. The difference between groups in reduction of mean VAS score from baseline was 2.6 (95% CI 1.74-3.37, pInterpretation In a subgroup of patients with acute osteoporotic vertebral compression fractures and persistent pain, percutaneous vertebroplasty is effective and safe. Pain relief after vertebroplasty is immediate, is sustained for at least a year, and is significantly greater than that achieved with conservative treatment, at an acceptable cost.

KW - QUALITY-OF-LIFE

KW - PERCUTANEOUS VERTEBROPLASTY

KW - FOLLOW-UP

KW - PAIN RELIEF

KW - KYPHOPLASTY

KW - IMPROVEMENT

U2 - 10.1016/S0140-6736(10)60954-3

DO - 10.1016/S0140-6736(10)60954-3

M3 - Article

VL - 376

SP - 1085

EP - 1092

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9746

ER -

ID: 5173206